p53 and breast cancer, an update - PubMed

Affiliations

• PMID: 16728565
• DOI: 10.1677/erc.1.01172

Review

p53 and breast cancer, an update

Marc Lacroix et al. Endocr Relat Cancer. 2006 Jun.

Abstract

p53 plays a key role in mediating cell response to various stresses, mainly by inducing or repressing a number of genes involved in cell cycle arrest, senescence, apoptosis, DNA repair, and angiogenesis. According to this important function, p53 activity is controlled in a very complex manner, including several auto-regulatory loops, through the intervention of dozens of modulator proteins (the 'p53 interactome'). p53 mutations are observed in a significant minority of breast tumours. In the remaining cases, alterations of interactome components or target genes could contribute, to some extent, to reduce the ability of p53 to efficiently manage stress events. While the prognostic and predictive value of p53 is still debated, there is an increasing interest for p53-based therapies. The present paper aims to provide updated information on p53 regulation and function, with specific interest on its role in breast cancer.

Similar articles

• A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.

  Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Børresen-Dale AL, Overgaard J. Alsner J, et al. Acta Oncol. 2008;47(4):600-7. doi: 10.1080/02841860802047411. Acta Oncol. 2008. PMID: 18465328

• Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells.

  Moh MC, Zhang T, Lee LH, Shen S. Moh MC, et al. Carcinogenesis. 2008 Dec;29(12):2298-305. doi: 10.1093/carcin/bgn226. Epub 2008 Oct 8. Carcinogenesis. 2008. PMID: 18845560

• TP53 status and response to chemotherapy in breast cancer.

  Bertheau P, Espié M, Turpin E, Lehmann J, Plassa LF, Varna M, Janin A, de Thé H. Bertheau P, et al. Pathobiology. 2008;75(2):132-9. doi: 10.1159/000123851. Epub 2008 Jun 10. Pathobiology. 2008. PMID: 18544968 Review.

• Human tumor suppressor p53 and DNA viruses.

  Collot-Teixeira S, Bass J, Denis F, Ranger-Rogez S. Collot-Teixeira S, et al. Rev Med Virol. 2004 Sep-Oct;14(5):301-19. doi: 10.1002/rmv.431. Rev Med Virol. 2004. PMID: 15334538 Review.

Cited by

• The immune system and inflammation in breast cancer.

  Jiang X, Shapiro DJ. Jiang X, et al. Mol Cell Endocrinol. 2014 Jan 25;382(1):673-682. doi: 10.1016/j.mce.2013.06.003. Epub 2013 Jun 19. Mol Cell Endocrinol. 2014. PMID: 23791814 Free PMC article. Review.

• Ethanolic extract of Origanum syriacum L. leaves exhibits potent anti-breast cancer potential and robust antioxidant properties.

  Mesmar J, Abdallah R, Hamade K, Baydoun S, Al-Thani N, Shaito A, Maresca M, Badran A, Baydoun E. Mesmar J, et al. Front Pharmacol. 2022 Oct 10;13:994025. doi: 10.3389/fphar.2022.994025. eCollection 2022. Front Pharmacol. 2022. PMID: 36299882 Free PMC article.

• C₂-Ceramide-Induced Rb-Dominant Senescence-Like Phenotype Leads to Human Breast Cancer MCF-7 Escape from p53-Dependent Cell Death.

  Chang WT, Wu CY, Lin YC, Wu MT, Su KL, Yuan SS, Wang HD, Fong Y, Lin YH, Chiu CC. Chang WT, et al. Int J Mol Sci. 2019 Sep 2;20(17):4292. doi: 10.3390/ijms20174292. Int J Mol Sci. 2019. PMID: 31480728 Free PMC article.

• A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation.

  Brekman A, Singh KE, Polotskaia A, Kundu N, Bargonetti J. Brekman A, et al. Breast Cancer Res. 2011 Jan 11;13(1):R3. doi: 10.1186/bcr2804. Breast Cancer Res. 2011. PMID: 21223569 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Sheridan PubFactory

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal